Inhibition of p53 expression by peptide-conjugated phosphorodiamidate morpholino oligomers sensitizes human cancer cells to chemotherapeutic drugs

Oncogene

Volumn 31, Issue 8, 2012, Pages 1024-1033

  Ma, W ^a   Lin, Y ^a   Xuan, W ^a   Iversen, P L ^b   Smith, L J ^c   Benchimol, S ^a  

^a YORK UNIVERSITY   (Canada)

^b AVI BIOPHARMA INC   (United States)

^c Eleos Inc   (United States)

Author keywords

chemosensitivity; morpholino antisense oligomers; p53 tumor suppressor protein

Indexed keywords

CELL PENETRATING PEPTIDE; DOXORUBICIN; FLUOROURACIL; MORPHOLINO OLIGONUCLEOTIDE; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIZATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; DOXORUBICIN; DRUG CARRIERS; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MORPHOLINOS; MUTANT PROTEINS; PEPTIDE CHAIN INITIATION, TRANSLATIONAL; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; RNA SPLICING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84857363885     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.300     Document Type: Article

References (41)

1. Abes R, Arzumanov A, Moulton H, Abes S, Ivanova G, Gait MJ et al. (2008). Arginine-rich cell penetrating peptides: design, structureactivity, and applications to alter pre-mRNA splicing by stericblock oligonucleotides. J Pept Sci 14: 455-460. (Pubitemid 351540906)
2. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B et al. (2009). A mutant-p53/Smad complex opposes p63 to empower TGFb-induced metastasis. Cell 137: 87-98.
3. Banks L, Matlashewski G, Crawford L. (1986). Isolation of humanp53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159: 529-534. (Pubitemid 16033297)
4. Bertheau P, Espie M, Turpin E, Lehmann J, Plassa LF, Varna M et al. (2008). TP53 status and response to chemotherapy in breast cancer. Pathobiology 75: 132-139. (Pubitemid 351820731)
5. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP et al. (2005). P53 isoforms can regulate P53 transcriptional activity. Genes Dev 19: 2122-2137. (Pubitemid 41330315)
6. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L et al. (1999). Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104: 263-269.
7. Courtois S, Verhaegh G, North S, Luciani MG, Lassus P, Hibner U et al. (2002). DN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wildtype p53. Oncogene 21: 6722-6728. (Pubitemid 35221914)
8. El-Deiry WS. (2003). The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22: 7486-7495. (Pubitemid 37487171)
9. Fei P, Bernhard EJ, El-Deiry WS. (2002). Tissue-specific induction of p53 targets in vivo. Cancer Res 62: 7316-7327. (Pubitemid 36025255)
10. Flaman JM, Waridel F, Estreicher A, Vannier A, Limacher JM, Gilbert D et al. (1996). The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene 12: 813-818. (Pubitemid 26072268)
11. Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ et al. (2009). p53 isoforms D133p53 and p53b are endogenous regulators of replicative cellular senescence. Nat Cell Biol 11: 1135-1142.
12. Ghosh A, Stewart D, Matlashewski G. (2004). Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 24: 7987-7997. (Pubitemid 39167449)
13. Gudkov AV, Komarova EA. (2003). The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 3: 117-129. (Pubitemid 37328879)
14. Harlow E, Crawford LV, Pim DC, Williamson NM. (1981). Monoclonal antibodies specific for simian virus 40 tumor antigens. J Virol 39: 861-869. (Pubitemid 11059884)
15. Harms KL, Chen X. (2006). The functional domains in p53 family proteins exhibit both common and distinct properties. Cell Death Differ 13: 890-897.
16. Horikawa I, Suzuki M, Oshimura M. (1995). An amino-terminally truncated p53 protein expressed in a human choriocarcinoma cell line, CC1. Hum Mol Genet 4: 313-314.
17. Iversen PL. (2001). Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Curr Opin Mol Ther 3: 235-238. (Pubitemid 32624571)
18. Kim E, Giese A, Deppert W. (2009). Wild-type p53 in cancer cells: when a guardian turns into a blackguard. Biochem Pharmacol 77: 11-20.
19. Koonin EV, Rogozin IB, Glazko GV. (2005). p53 gain-of-function: tumor biology and bioinformatics come together. Cell Cycle 4: 686-688. (Pubitemid 41353853)
20. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. (2004). Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872. (Pubitemid 40017691)
21. Lim LY, Vidnovic N, Ellisen LW, Leong CO. (2009). Mutant p53 mediates survival of breast cancer cells. Br J Cancer 101: 1606-1612.
22. Lohrum MA, Woods DB, Ludwig RL, Bálint E, Vousden KH. (2001). C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol 21: 8521-8532. (Pubitemid 33108611)
23. Lowe SW, Ruley HE, Jacks T, Housman DE. (1993a). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967. (Pubitemid 23289454)
24. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. (1993b). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849. (Pubitemid 23132161)
25. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T et al. (2004). Modulation of mammalian life span by the short isoform of p53. Genes Dev 18: 306-319. (Pubitemid 38199255)
26. McGill G, Fisher DE. (1999). P53 and cancer therapy: a double-edged sword. J Clin Invest 104: 223-225.
27. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S et al. (2009). Mutant p53 drives invasion by promoting integrin recycling. Cell 139: 1327-1341.
28. Nakamura S, Roth JA, Mukhopadhyay T. (2000). Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol Cell Biol 20: 9391-9398. (Pubitemid 32246123)
29. Nelson MH, Stein DA, Kroeker AD, Hatlevig SA, Iversen PL, Moulton HM. (2005). Arginine-rich peptide conjugation to morpholino oligomers: Effects on antisense activity and specificity. Bioconjug Chem 16: 959-966. (Pubitemid 41026180)
30. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M et al. (1997). Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300. (Pubitemid 27413438)
31. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. (2004). Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860. (Pubitemid 40017690)
32. Ray PS, Grover R, Das S. (2006). Two internal ribosome entry sites mediate the translation of p53 isoforms. EMBO Rep 7: 404-410.
33. Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT. (2000). Multiple C-terminal lysine residues target p53 for ubiquitinproteasome-mediated degradation. Mol Cell Biol 20: 8458-8467.
34. Rovinski B, Munroe D, Peacock J, Mowat M, Bernstein A, Benchimol S. (1987). Deletion of 50-coding sequences of the cellular p53 gene in mouse erythroleukemia: a novel mechanism of oncogene regulation. Mol Cell Biol 7: 847-853. (Pubitemid 17004551)
35. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Sigfried Z et al. (2010). Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 17: 273-285.
36. Summerton J, Weller D. (1997). Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7: 187-195. (Pubitemid 27323077)
37. Vousden KH, Prives C. (2009). Blinded by the light: the growing complexity of p53. Cell 137: 413-431.
38. Wang C, Curtis JE, Minden MD, McCulloch EA. (1989). Expression of a retinoic acid receptor gene in myeloid leukemia cells. Leukemia 3: 264-269. (Pubitemid 19092758)
39. Wu RP, Youngblood DS, Hassinger JN, Lovejoy CE, Nelson MH, Iversen PL et al. (2007). Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res 35: 5182-5191. (Pubitemid 47394201)
40. Yin Y, Stephen CW, Luciani MG, Fahraeus R. (2002). p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 4: 462-467. (Pubitemid 34746166)
41. Zhu J, Zhou W, Jiang J, Chen X. (1998). Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J Biol Chem 273: 13030-13036. (Pubitemid 28246867)